An integrated valuation model for payer and investor

Background In order to optimize positioning and associated drug price for both payer and investor, it is for a company essential to forecast the potential market access attractiveness for the new drug for different indications at the early onset of the clinical development program. This analysis mus...

Full description

Bibliographic Details
Main Authors: Mark Nuijten, Stefano Capri
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Market Access & Health Policy
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/20016689.2022.2080631